BiotechTV

Channel · 5 Shows

Life Sciences

Life Sciences

Updated Biweekly
Life Sciences

Life Sciences

Updated 5d ago
Life Sciences

Life Sciences

Updated Jun 25
Life Sciences

Life Sciences

Updated Apr 16
Life Sciences

Life Sciences

Updated Oct 19

Nov 2

Episode 51: Vianti Capital's Arjun Goyal

With an immigrant upbringing that took him to Australia, where he practiced medicine, and the UK, where he went to graduate school, before coming to the U.S. for a startup he co-founded and Harvard Business School, Arjun Goyal describes learnings along the way. He discusses his extensive experience in the venture world, first at 5AM Ventures and then Vida Ventures, before more recently founding Vianti Capital.
Oct 19

Episode 50: Third Rock Ventures' Bob Tepper

the early days of the biotech sector before it was common, the founding of Third Rock Ventures, and the unique culture at Third Rock that has produced so many investors and company builders who have achieved great things in their careers.
4d ago

From Montreal: Congruence Therapeutics uses computational discovery to develop novel small molecule correctors and allosteric modulators - its lead program is for a high profile genetic obesity target

Founder & CEO Clarissa Desjardins describes Congruence's Revenir product engine and walks us through programs that include MC4R deficient obesity, which is in the clinic, alpha-1 antitrypsin deficienty, and Parkinson's.
Oct 29

After presenting data at ESMO this past weekend, Tango Therapeutics believes that adding PRMT5 to RAS inhibitors represents the 'next chapter' in today's pancreatic cancer revolution (and beyond)

President and CEO Malte Peters summarizes the ESMO data for vopemetistat, which was in second and third line pancreatic cancer in combination with daraxonrasib, and discusses plans for a phase 3 in first line (plus the regulatory path for later lines as well). Additionally, he discusses using PRMT5 inhibition in lung cancer and GBM.
5d ago

From Montreal: A panel of top venture investors who are based in Montreal discuss the state of biotech in the area and across Canada

Sofinnova Investments' Maha Katabi, Finchley Healthcare Ventures' Pierre Beauparlant, and Amplitude Ventures' Jean-Francois Pariseau describe the biotech scene here, what Montreal and other Canadian biotech hubs do well, what could be improved, and the environment for entrepreneurs to turn ideas into companies.
Oct 5

Episode 49: Sanofi Ventures' Jason Hafler

Jason Hafler shares an overview of the corporate side of the venture world. He describes the unique value that he believes a corporate based VC can bring to the companies it invests in. Plus, his description of cases where investments might ultimately be a good fit for BD and/or M&A within the company, and why an investment might ultimately land at a different suitor.
6d ago

Abingdon, UK based T-Cypher Bio believes that the future of T-cell engagers will focus on intracellular targets - preclinical data on two novel targets, TC25 & TC11, will be at SITC

CEO Sarah Leonard describes the company's focus and process. The lead program, TC25, is scheduled to be in the clinic in 2028, and the company also has plans to go after auto-immune conditions in addition to oncology.
Oct 7

Eli Lilly Chairman & CEO David Ricks discusses GLP-1's, Alzheimer's, business development and more

From the company's headquarters in Indianapolis, he describes where he thinks the obesity field could be headed in the next few years, what might be next after beta-amyloid in Alzheimer's, and how he plans to invest for the future.
5d ago

Oxford based Alethio Therapeutics unveiled a $90M Series A today to advance its therapies for myeloproliferative neoplasms, and also announced for the first time that ATX-011's target will be G6B

CEO Rohit Batta describes the unmet need in myeloproliferative neoplasms and the rational for targeting G6B, a protein expressed on platelets and megakaryocytes. Their pre-clinical work just earned Alethio an oral presentation at the upcoming ASH Annual Meeting.
Oct 27

At its R&D Day in London today, Gubra provided updates on obesity assets licensed to AbbVie and Boehringer Ingelheim, as well as highlighted its lead internal program UCN2

CEO Markus Rohrwild and CDMO Thomas Langenickel provide an update on the company's peptide based drug development side, as well as venture and CRO arms.

BiotechTV covers the biotechnology sector through news, stories, podcasts, and educational videos.

Website

BiotechTV

Top Shows

Episode 51: Vianti Capital's Arjun Goyal

Episode 50: Third Rock Ventures' Bob Tepper

From Montreal: Congruence Therapeutics uses computational discovery to develop novel small molecule correctors and allosteric modulators - its lead program is for a high profile genetic obesity target

After presenting data at ESMO this past weekend, Tango Therapeutics believes that adding PRMT5 to RAS inhibitors represents the 'next chapter' in today's pancreatic cancer revolution (and beyond)

From Montreal: A panel of top venture investors who are based in Montreal discuss the state of biotech in the area and across Canada

Episode 49: Sanofi Ventures' Jason Hafler

Abingdon, UK based T-Cypher Bio believes that the future of T-cell engagers will focus on intracellular targets - preclinical data on two novel targets, TC25 & TC11, will be at SITC

Eli Lilly Chairman & CEO David Ricks discusses GLP-1's, Alzheimer's, business development and more

Oxford based Alethio Therapeutics unveiled a $90M Series A today to advance its therapies for myeloproliferative neoplasms, and also announced for the first time that ATX-011's target will be G6B

At its R&D Day in London today, Gubra provided updates on obesity assets licensed to AbbVie and Boehringer Ingelheim, as well as highlighted its lead internal program UCN2

About

BiotechTV

Top Shows

Top Episodes

About